In contrast, the combination of the pancreatic cancer GVAX vaccine (with low-dose cyclophosphamide), nivolumab, and urelumab (an anti-CD137 agonist antibody that enhances T-cell immunity) as adjuvant or neoadjuvant therapy in patients with resectable pancreatic cancer has demonstrated potential efficacy. This evidence concerns the gene TNFRSF9 and familial pancreatic carcinoma.